Introduction
The CD21 molecule [the complement receptor type 2 (CR2)] functions as a receptor for the surface-bound iC3b/C3dg/ C3d fragments of human C3, for the low-affinity receptor for IgE, CD23, and for Epstein-Barr virus (EBV) (1) (2) (3) . CD21 is a transmembrane molecule of 145 kDa, consisting of a large extracellular domain of 15 or 16 tamdemly repeated short consensus repeat sequences followed by a transmembrane region and a short intracytoplasmic domain (4) . In the membrane of mature B cells, CD21 is in the form of a stable complex with CD19 and TAPA-1 (5, 6) . The interaction of CD21 with C3 and CD23 was shown to enhance B cell activation, proliferation, differentiation into IgE-producing cells and to rescue germinal center B cells from apoptosis (2, (7) (8) (9) . The binding of EBV to CD21 on B cells is followed by endocytosis Correspondence to: E. Fischer Transmitting editor: G. Klein Received 30 April 1999, accepted 27 July 1999 of the CD21/virus complex (10, 11) . EBV infection of B cells alters their growth, which may result in autoantibody production and in B cell malignancy (12, 13) . In addition to B cells, CD21 is expressed on thymocytes, a subset of peripheral T lymphocytes, follicular dendritic cells, astrocytes and some epithelial cells (14) (15) (16) (17) (18) . The functions of CD21 on human cells of the T lineage remain unclear. CD21 was, however, demonstrated to mediate an increased concentration of Ca i 2ϩ , and to cap and internalize ligands on cells of the human HPB-ALL T cell line (19) . We have previously demonstrated that the expression of CD21 extends to both immature and mature thymocytes, and identified an immature subset of CD3 -CD1 ϩ large thymocytes that expresses CD21 with high density, suggesting a role for CD21 in the proliferation and/or differentiation of early thymocytes (20) . In the present study, we demonstrate that CD21 is differentially expressed on thymocytes during thymic maturation. We have enriched thymocytes in immature CD21 ϩϩ cells to investigate the functional consequences of the ligation of the receptor with iC3b, CD23 and EBV.
Methods

Antibodies and reagents
Anti-CD21 mAb HB5 (ATCC, Rockville, MD), BL13 (a gift from J. Brochier, Montpellier, France) and anti-CD35 mAb J3D3 (21) were biotinylated using biotin-X-NHS (France Biochem, Meudon, France. The isotypic control mAb MOPC21 (IgG1) and UPC10 (IgG2a) were purshased from Cappel (Cochranville, PA). FITC-conjugated mAb against CD2 (Leu5b), CD3 (Leu4), CD4 (Leu3a), CD34 (HPCA-2), CD19, phycoerythrin (PE)-conjugated mAb against CD8 (Leu2a) and streptavidin(SA)-PE were obtained from Becton Dickinson (Le Pont de Claix, France). FITC-anti-CD45 mAb and FITCanti-CD1a mAb (OKT6) were purchased from Immunotech (Marseille, France) and Ortho Diagnostics (Raritan, NJ) respectively. Recombinant human IL-7 and IL-1β were from Genzyme (Cambridge, MA).
Immunofluorescence
For immunofluorescence studies, cells (3ϫ10 5 ) were stained with fluorescent or with biotinylated (0.5 µg) mAb in PBS containing 2% normal AB serum for 30 min at 4°C. Biotinylated mAb were revealed by further incubation with SA-PE for 20 min. After two washes, cells were fixed in PBS containing 1% formaldehyde. Fluorescence was analyzed using a FACScan (Becton Dickinson) and the CellQuest software. Statistical analysis was performed using Student's t-test.
In situ, fluorescent studies were performed on frozen sections. Acetone-fixed 5 mm frozen thymic sections were incubated with biotinylated anti-CD21 mAb HB5 (dilution 1/3) overnight, followed by three washes in PBS and then revealed with avidin-FITC (Amersham, Les Ulis, France) or avidinTexas Red (Amersham) at a 1/100 dilution. Three antibodies were used for double-staining analysis: (i) to visualize the epithelial network, polyclonal anti-keratin antibodies (Dako, Trappes, France) were used at a 1/100 dilution and revealed with goat anti-mouse Ig-TRITC (Immunotech) at a 1/60 dilution for 30 min; (ii) to visualize the vessel structures, mouse monoclonal anti-α-smooth muscle actin antibodies (Dako) were used at a 1/50 dilution and then revealed with rat antimouse Ig-Texas Red (Dako) at 1/40 dilution for 30 min; and (iii) to visualize the thymic precursor cells, anti-CD34 mAb coupled to FITC (Becton Dickinson) was used at half dilution for 60 min. Sections were then washed 3 times in PBS and mounted under coverslips with glycerol/PBS. Control sections were incubated with the fluorescent conjugates. We also checked that same the results were obtained in simple-and double-fluorescence experiments.
Cell isolation
Human thymus (discarded tissue) was obtained from children Ͻ1 year of age undergoing cardiac surgery. Thymus tissue was minced and cells were collected by Ficoll-Hypaque gradient centrifugation. For phenotypic analysis, thymocytes were positively selected by rosetting with AET-treated sheep red blood cells. For isolation of thymocytes expressing CD21 at high density, the thymocyte suspension was sequentially incubated in RPMI containing 1% SVF with magnetic beads (Dynabeads M-450; Dynal, Compiè gne, France) coated with anti-CD3 (3 beads/cell), anti-CD8 (4 beads/cell) and anti-CD19 (1 bead/cell) for 30 min at 4°C.
Culture conditions
The iC3b fragment of human C3 was obtained as previously described (22) . The 25 kDa recombinant form of soluble (s) CD23 was a gift of J. Y. Bonnefoy (Glaxo, Plan les Ouates, Switzerland). Murine CD23-and mock-transfected L cells were cultured under selection pressure as previously reported (23) . Thymocytes that had been depleted in CD3 ϩ , CD8 ϩ and CD19 ϩ cells were cultured at 0.5ϫ10 6 /ml in RPMI 1640 supplemented with L-glutamine (2 mM), penicillin (100 U/ml), streptomycin (100 µg/ml) and 10% FCS in flat-bottom 96-well microplates. In selected experiments, thymocytes were incubated with rIL-7 (0.5-5ng/ml) in the presence of iC3b (20 µg/ml) or sCD23 (10 µg/ml). In additional experiments, iC3b and sCD23 were coated on the culture microplate for 18 h at 4°C prior to addition of the cells. Thymocytes were also co-cultured at different cell to cell ratios with CD23-or mock-transfected L cells that had been pretreated for 2 h with 50 µg/ml mitomycin C, in the presence of IL-7 or IL-1β (100 U/ml). Cultures were maintained for 3 days in 5% CO 2 at 37°C before being pulsed with 0.5 µCi of [ 3 H]thymidine (ICN, Orsay, France) for 16 h. Incorporation of thymidine was measured in a Micro-β plate (Wallac, Turku, Finland).
Immunoprecipitation
Thymocytes expressing CD21 at high density (CD21 ϩϩ ) (10 7 /ml) were reacted with PBS containing biotin-X-LHS 5 mM for 30 min at 4°C and washed twice with PBS containing 20 mM glycine. The cells were then lysed with 20 mM Tris, 150 mM NaCl, 1 mM EDTA buffer, pH 7.5, containing 0.1% Brij 96, and 1 mM PMSF, 2 µM leupeptin, 10 µM pepstatin and 8 µg/ml aprotin. The lysate was submitted to four preclearing steps using Sepharose-Protein coated with control mAb UPC10 and MOPC21 (5 µg of each). Immunoprecipitation was then performed either with anti-CD21 mAb HB5 and BL13 (5 µg of each) or with isotype-matched mAb for 2 h at 4°C. Immunoprecipitates were electrophoresed on 8% SDS-PAGE under reducing conditions and then blotted on nitrocellulose membranes (Schleicher, Dassel, Germany) in 25 mM Tris/192 mM glycine buffer containing 20% ethanol for 90 min. The membranes were saturated, incubated with SA peroxidase (Amersham) and then revealed by chemiluminescence using the ECL kit (Amersham). Ten million Raji B lymphoblastoid cells (ATCC) were processed in a parallel fashion as a positive control.
Results
Stage-specific expression of CD21 during human thymocyte differentiation We first confirmed our previous observations of the presence of two distinct subpopulations of human thymocytes, one expressing CD21 with high (CD21 ϩϩ ) intensity and the other expressing low amounts of CD21 (CD21 ϩ ), by analyzing CD2 ϩ cells isolated from 11 freshly obtained human thymuses (20) . High levels of CD21 (MFI: 320 Ϯ 42) were expressed by 11 Ϯ 5% thymocytes, whereas 58 Ϯ 10% of cells expressed a low density of the receptor (MFI: 48 Ϯ 6). In order to analyze the expression of CD21 during T cell differentiation, we then used three-color staining with FITC-Leu3a, PerCP-Leu2a and biotinylated HB5 mAb. We defined discrete stages of differentiation based on the expression of CD4 and CD8, and analyzed the relative intensity of staining for CD21 antigen on gated cells. Figure 1 shows a representative staining experiment performed on CD2 ϩ thymocytes. The findings obtained upon analysis of cells of nine thymuses are summarized in Fig. 2 . The percentage of cells expressing CD21 did not differ significantly between CD4 -CD8 -double-negative (DN) cells (67 Ϯ 6%), intermediate CD4 low CD8 -cells (62 Ϯ 7%) and CD4 ϩ CD8 ϩ double-positive (DP) common thymocytes (65 Ϯ 6%). The proportion of CD21-expressing cells was, however, markedly decreased upon differentiation of DP cells into CD4 ϩ single-positive (SP) cells (34 Ϯ 5%), although it remained stable upon differentiation of DP cells into CD8 ϩ SP cells (75 Ϯ 5%). The mean fluorescent intensity (MFI) of staining for CD21 was significantly higher on CD4 -CD8 -DN cells (305 Ϯ 79) and CD4 low CD8 -cells (219 Ϯ 66) than on cells at later stages of differentiation (Fig. 2) . The density of CD21 on thymocytes was similar on DP CD4 ϩ CD8 ϩ cells (98 Ϯ 28), SP CD4 ϩ cells (88 Ϯ 25) and SP CD8 ϩ cells Fig. 2 . Expression of CD21 on thymocytes during differentiation. CD2 ϩ thymocytes of nine freshly obtained thymuses were stained as described in Fig. 1 . The MFI of staining is plotted at each stage of differentiation, as indicated on the abcissa. The MFI was significantly higher on CD4 -CD8 -as compared with cells at other stages of differentiation (P Ͻ 0.0001) and on CD4 low CD8 -as compared with cells at other stages of differentiation (P ranging between 0.0001 and 0.005).
(73 Ϯ 21). There was increased expression of CD21 on CD4 ϩ CD8 low cells (134 Ϯ 21), which may reflect the heterogeneity of this population that contains cells reaching the DP stage and cells losing the expression of the CD8 marker to become SP CD4 ϩ cells. Staining with anti-CD45 antibodies indicated that CD45RA ϩ thymocytes expressed CD21 with a higher intensity (230 Ϯ 100) than CD45RO ϩ cells (87 Ϯ 25).
Staining of total thymic cell suspensions for CD21 revealed that, in addition to T cells, 1.5% of CD21 ϩ cells were B cells co-expressing CD19 and CD21 (MFI for CD21: 537). No staining for CD21 was observed on CD19 -CD2 -cells, indicating that thymocyte precursors and stromal cells in the thymus do not express the CD21 receptor (data not shown). Taken together, our data indicate that the expression of CD21 is regulated throughout thymocyte differentiation, with maximal expression at the CD4 -CD8 -DN stage and at the early stage of acquisition of the CD4 marker by thymocytes.
In order to localize CD21 ϩ cells, we performed doublestaining experiments on frozen thymic sections. Double staining with anti-α-smooth muscle actin antibodies indicated that CD21 ϩ cells are located around the vessels (Fig. 3) . Anti-CD21 antibody not only stains some thymocytes but also recognizes some structure proteins on the vessel (Fig. 3) . Anti-keratin antibodies were used to identify the epithelial network. CD21 ϩ cells were found to be close to the subcapsular epithelial network, particularly at sites where the epithelial subcapsular line presents discontinuities (Fig. 3) . Finally, double staining with anti-CD34 antibodies, identifying early thymic precursor cells, demonstrated that some CD21 ϩ cells in the thymus, co-express CD34. The localization of CD21 ϩ cells close to the vessels and discontinuities of the epithelial subcapsular line are compatible with the hypothesis that the CD21 ϩ cells have recently migrated.
Properties of thymocytes selected for the expression of CD21 at high density Thymocytes were enriched in CD21 ϩϩ cells by depleting thymic cell suspensions in CD3 ϩ , CD8 ϩ and CD19 ϩ cells, using magnetic beads coated with the relevant mAb. The selection process was performed on five thymuses, yielding 5% of the initial thymocyte number. The phenotype of the CD21 ϩϩ -enriched cells obtained in this way is depicted in Fig. 4 . CD21 ϩϩ cells expressing a MFI of 288, accounted for 71% of the cells. CD21 ϩϩ -enriched cells positively stained for the CD2 antigen, did not express CD3 nor CD8, and did not contain DP CD4 ϩ CD8 ϩ thymocytes. Forty-four percent of the CD21 ϩϩ -enriched cells expressed CD4, 23% expressed CD34, 9% expressed CD69, 18% expressed CD45RA and 17% expressed CD45RO. CD21 ϩϩ -enriched cells displayed a larger size (FSC: 511) than unfractionated thymocytes (FSC: 386) (data not shown). The CD21 ϩϩ thymocytes were then used in functional experiments. The cells were found not to proliferate in the presence of IL-1, IL-2 or IL-4, nor in the presence of anti-CD2 mAb (data not shown). CD21 ϩϩ thymocytes responded, however, to IL-7, a key growth-promoting factor for the expansion of immature CD3 -TCR -thymocytes (24) (Fig. 5 ). Proliferation was decreased upon depletion of the cell suspension in CD34 ϩ cells. We further investigated whether the ligation of CD21 on CD21 ϩϩ thymocytes modulates their ability to respond to IL-7. No effect of triggering CD21 with anti-CD21 mAb HB5 and BL-13, recombinant CD23 or purified iC3b, whether added in soluble form or immobilized on culture wells, was observed with regard to IL-7-induced proliferation (data not shown). In addition, the co-culture of thymocytes with CD23-transfected murine L cells did not alter the rate of IL-7-induced proliferation of CD21 ϩϩ thymocytes as compared with that of cultures performed in the presence of wildtype L cells (data not shown).
Since CD23 has been reported to induce the differentiation of pro-thymocytes in the presence of IL-1 (25), we cultured CD21 ϩϩ thymocytes with CD23-or mock-transfected murine L cells in the presence of recombinant human IL-1β (100 U/ml), and assessed the cells for the expression of CD3, CD4, CD8, CD1, CD69, CD38 and CD34 after 3 days of culture. No change in phenotype of the cells was observed (data not shown).
We then assessed the capacity of EBV, as an additional CD21 stimulus, to modulate the phenotype of CD21 ϩϩ thymocytes. EBV induced a dramatic decrease in the expression of CD21 (Fig. 6) . A selective decrease in cells expressing CD21 at high density was also observed in CD3 ϩ -depleted thymocytes, suggesting that CD21 ϩϩ thymocytes are the preferential target for virus binding and internalization. The expression of CD1 and, to a lesser extent, of CD4 and CD8, was increased. Of note, however, was the fact that a part of thymocytes that were CD8 -and CD4 low at the initiation of the culture acquired these markers upon 3 days of culture in the absence of EBV. The expression of CD3 was unchanged, whether the cells had been cultured in the presence or absence of EBV (data not shown). Although no proliferation of cells was induced by EBV, we observed a 2-fold increase in the viability of CD21 ϩϩ thymocytes cultured in the presence of EBV for 3 days, as compared with cells cultured in medium alone.
Since CD21 signals in B cells through a complex involving CD19 and TAPA-1, we investigated whether CD21 is associated with a transducing protein in the membrane of thymo- 4 . Phenotypic characterization of the subpopulation of thymocytes enriched in CD21 ϩϩ cells. A freshly obtained thymocyte suspension was subjected to negative selection using magnetic beads coated with anti-CD3 -, anti-CD8 -and anti-CD19 -mAb. The phenotype of the resulting population was then assessed using twocolor fluorescence for the expression of CD2, CD3, CD4, CD8 and CD21.
cytes. Membranes of CD21 ϩϩ thymocytes were lyzed under mild conditions using Brij 96. As shown in Fig. 7 , anti-CD21 mAb immunoprecipitated a single protein of 145 kDa from the lysates, corresponding to CD21. Under the same experimental conditions, anti-CD21 mAb immunoprecipitated CD19, TAPA-1, p 40 and p 130 in addition to CD21, in Raji cell lysates, as previously described by Matsumoto et al. (5) .
Discussion
In the present study, we demonstrate that, as it is known to be the case for cells of the B lineage, the expression of the CD21 receptor is developmentally regulated during maturation of human T lymphocytes.
In contrast to B cells that maximally express CD21 at a mature stage, thymocytes express the highest density of CD21 at the most immature DN stage of intra-thymic differentiation as well as at the stage of early acquisition of the CD4 antigen. The density of CD21 on DN thymocytes was found to be in the same range as that expressed on the few B cells present in the thymus. It is unlikely that the high expression of the molecule was merely related to the large size of immature thymocytes. Thus, small B cells in early G 1 phase express a greater density of receptor per unit membrane than larger G 2 /M and S phase cells (26) ; in addition, the density of CD35 was similar on immature and mature thymocytes, irrespective of size (A. Mouhoub, unpublished data). Upon transition to the DP stage the expression of CD21 decreased so as to reach, at further stages of differentiation, a density equivalent to that observed on peripheral blood T lymphocytes (16) . However, whereas the percentage of CD21 ϩ cells is similar on peripheral blood CD4 ϩ and CD8 ϩ lymphocytes, we found it to be significantly higher on SP CD8 thymocytes than SP CD4-expressing thymocytes. These results suggest that the expression of CD21 on CD8 ϩ thymocytes is lost at the time of their last phenotypic switch before the cells emigrate from the thymus to the periphery or, alternatively, that some CD8 ϩ CD21 ϩ thymocytes become trapped in a secondary lymphoid organ. The immature phenotype of thymocytes that express the highest density of CD21 was further confirmed by their localization in the sub-capsular region of the thymus, close to vessels and by the co-expression of the CD34 antigen by some of the cells. The present observations together with previous data from our laboratory (20) and from Schmitt et al. (27) suggest the following sequence of changes in phenotypic patterns during intra-thymic differentiation of human T lymphocytes: 
The expression of CD21 is tightly controlled during the maturation process of B lymphocytes. Whereas the receptor is undetectable on immature B cells, it is fully expressed on IgM ϩ IgD ϩ mature cells and then lost at the plasma cell stage (28) . Binding sites for the transcription factors SP1 and AP-1/AP-2 are present in the CD21 promoter-containing region (-1253/ϩ75), but no regulatory elements that control cell or stage-specific transcription of the CD21 gene have as yet been identified in this region (29) . Recently, however, an intronic silencer gene segment (CRS) has been characterized that confers stage-specific expression of a reporter gene under control of the CD21 proximal promoter following stable transfection of B cell lines (30) . Although CD21 is not expressed on murine thymocytes, the thymus of mice transgenic for the CRS expressed the reporter gene, suggesting that the construct directs CD21 expression in a human pattern on T cells in this model (30) . Such a control of gene expression by an intronic silencer in combination with an active promoter has also been described in thymocytes with regard to CD4 (31) .
Proliferation is mostly restricted to the CD4 -CD8 -and early TCR -populations of thymocytes (24) . IL-7, which is produced by thymic stromal cells, appears to play a major role during early proliferative stages of thymocyte maturation (32) . Since CD21 triggers the proliferation of B cells (8), we investigated the effects of CD21 ligation on IL-7-induced proliferation of purified CD21 ϩϩ -expressing early thymocytes. These cells represent high CD21-expressing primary T cells. Soluble/ immobilized anti-CD21mAb, iC3b and soluble/cell-associated CD23 were ineffective in modulating the proliferative response of early thymocytes to IL-7. CD23-transfectants used in these experiments were, however, able to cause a 10-to 100-fold reduction in the concentration of anti-IgM required for B cell proliferation (23) . Anti-CD21 mAb were also reported to be ineffective in enhancing the proliferation of unfractionated thymocytes to anti-CD2 and/or IL-2 (33). Although Mossalayi et al. ascribed a role for CD23 in prothymocyte maturation (25), we did not observe any phenotypic change upon coculture of CD21 ϩϩ thymocytes with CD23-transfected cells, suggesting that CD21 is not the receptor involved in the transduction of a maturation signal. Furthermore, we found no evidence of association of a transducing molecule with CD21 in the membrane of immature thymocytes. In contrast to B cells where CD21 is complexed with the transducing molecule CD19, CD21 was not part of a preformed complex in the membrane of resting thymocytes. The lack of association of CD21 with a potentially transducing protein has also been reported by Prodinger upon analysis of immunoprecipitates of human T cell lines (34) . Thymocyte-stromal cell interaction is a two-way process in which the development and maintenance of stromal cell function is dependent upon the influence of developing thymocytes (35) . Since CD23-specific mRNA has been detected in thymic epithelial cells of the outer cortex (36), we suggest that CD21 on early thymocytes acts as a ligand for CD23-expressing cells in the thymus.
The presence of the EBV genome has been reported in several T cell malignancies. The expression of CD21 may thus provide a route for entry of the virus into cells of the T lineage. Suspensions of unfractionated human thymocytes have been reported to be infected by EBV and to allow the transcription of viral genes in the absence of cell immortalization (33, 37, 38) . The dramatic down-regulation of CD21 induced by EBV that we observed on CD21 ϩϩ thymocytes was likely due to the internalization of the EBV-CD21 complex since we found a concommitant decrease in the expression of CD35. CD35 was previously demonstrated to be coexpressed with CD21 in CD4 -CD8 -thymocytes (20) and to co-internalize with CD21 in the HPB-ALL T cell line (19) . Intact virions have been detected in membrane-bound cellular vesicles in the CD21-expressing leukemic T cell line HPB-ALL (39) . In accordance with a previous report (39), we also provide evidence that infection with EBV up-regulates the CD1a antigen in purified immature thymocytes. EBV-induced phenotypic changes of infected thymocytes may be related to the expression of viral transactivating factors such as ZEBRA (40) which was shown to interfere with cellular transcription factors (41, 42) .
Taken together, our data provide evidence for a regulated expression of CD21 during intrathymic maturation of human T cells and suggest that the high CD21-expressing subset of immature thymocytes may be a target for infection with EBV. Since the transcription of EBV genes alters the function of RAG which is active in recombination of TCR genes in immature thymocytes (43) , our data could be relevant to pathological processes of selection of repertoires in human T cells.
